Companies
/Healthcare
Incyte Corp
$117.80
▼ $1.29 (−1.08%) today
Markets closed · 12:25am ET
Incyte (INCY) Earnings History & Trends
86%
EPS beat rate
+19.18%
Avg. EPS surprise
Consecutive EPS beats
INCY vs Market · 30-day return after each reportINCYS&P 500
INCY EPS Trend · estimate vs actualEstimateActual
INCY Revenue Trend · estimate vs actualEstimateActual
How Often Does Incyte Beat Earnings Estimates?
Incyte beat EPS estimates in 6 of its last 7 reported quarters, and has beaten 3 quarters in a row.
| Quarter | EPS · est. | Surprise | Revenue · est. | Surprise |
|---|---|---|---|---|
| Q3 2026 Includes a one-time $1.23 billion IPR&D expense related to the acquisition of Vega Therapeutics (included in both GAAP and non-GAAP R&D); GAAP diluted EPS was $(3.86). | $-3.60 est. $-3.84 | +6.14% | $1.6B est. $1.5B | +5.55% |
| Q2 2026 | $3.09 est. $2.15 | +43.95% | $1.7B est. $1.5B | +12.50% |
| Q1 2026 | $1.81 est. $1.34 | +35.13% | $1.3B est. $1.2B | +5.07% |
| Q4 2025 | $1.80 est. $1.92 | −6.08% | $1.5B est. $1.4B | +11.33% |
| Q3 2025 | $2.26 est. $1.64 | +38.04% | $1.4B est. $1.3B | +8.96% |
| Q2 2025 | $1.57 est. $1.47 | +6.48% | $1.2B est. $1.1B | +5.81% |
| Q1 2025 | $1.16 est. $1.05 | +10.62% | $1.1B est. $996.6M | +5.65% |
Figures from SEC filings and company reports. Not investment advice.